Intensity Therapeutics, Inc. (INTS)
NCM · Healthcare · Biotechnology
$3.62
-1.36%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$9.8M
Shares Outstanding
2.7M
Exchange
NCM
Currency
USD
About Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -2.7M | -2.7M | -3.1M | -2.5M |
| Net Income | -2.5M | -2.7M | -3.1M | -2.4M |
| Diluted EPS | $-3.25 | $-1.50 | $nan | $-0.96 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -7.5M | -8.3M | -16.6M | -12.0M |
| Net Income | -7.6M | -10.5M | -16.3M | -11.6M |
| Diluted EPS | $-54.73 | $-34.50 | $-29.24 | $-8.56 |